These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 2821397

  • 1. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.
    Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL, Levey AS.
    N Engl J Med; 1987 Oct 22; 317(17):1049-54. PubMed ID: 2821397
    [Abstract] [Full Text] [Related]

  • 2. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC.
    N Engl J Med; 1999 May 13; 340(19):1462-70. PubMed ID: 10320384
    [Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, Rohrer R.
    Clin Transplant; 1997 Oct 13; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [Abstract] [Full Text] [Related]

  • 4. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B, Thomas CD, Radovancevic R, Frazier OH, Radovancevic B.
    J Heart Lung Transplant; 2004 Apr 13; 23(4):461-5. PubMed ID: 15063406
    [Abstract] [Full Text] [Related]

  • 5. Polyvalent immune globulin and cytomegalovirus infection after renal transplantation.
    Kasiske BL, Heim-Duthoy KL, Tortorice KL, Ney AL, Odland MD, Rao KV.
    Arch Intern Med; 1989 Dec 13; 149(12):2733-6. PubMed ID: 2556978
    [Abstract] [Full Text] [Related]

  • 6. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
    Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A.
    Clin Transplant; 2008 Dec 13; 22(1):89-97. PubMed ID: 18217909
    [Abstract] [Full Text] [Related]

  • 7. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
    Valenza M, Czer LS, Pan SH, Aleksic I, Freimark D, Harasty DA, Admon D, Barath P, Blanche C, Trento A.
    J Heart Lung Transplant; 1995 Dec 13; 14(4):659-65. PubMed ID: 7578172
    [Abstract] [Full Text] [Related]

  • 8. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.
    Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM.
    N Engl J Med; 1992 Apr 30; 326(18):1182-6. PubMed ID: 1313549
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D, Saldan A, Fiscon M, Cofano S, Paciolla A, Furian L, Ekser B, Biasolo MA, Cusinato R, Mengoli C, Bonfante L, Rossi B, Rigotti P, Sgarabotto D, Barzon L, Palù G.
    J Infect Dis; 2010 Aug 15; 202(4):585-94. PubMed ID: 20594105
    [Abstract] [Full Text] [Related]

  • 10. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T, Ljungman P, Brinch L, Lenhoff S, Lönnqvist B, Ringdén O, Ruutu P, Volin L, Albrechtsen D, Sallerfors B, Ebeling F, Myllylä G.
    Bone Marrow Transplant; 1997 Feb 15; 19(3):233-6. PubMed ID: 9028551
    [Abstract] [Full Text] [Related]

  • 11. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR, Fullerton DA, Campbell DN, Leone S, Diercks MJ, Fisher JH, Badesch DB, Grover FL.
    Transplant Proc; 1994 Oct 15; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [Abstract] [Full Text] [Related]

  • 12. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Oct 15; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 13. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation.
    Peterson PK, Balfour HH, Marker SC, Fryd DS, Howard RJ, Simmons RL.
    Medicine (Baltimore); 1980 Jul 15; 59(4):283-300. PubMed ID: 6248718
    [Abstract] [Full Text] [Related]

  • 14. [Clinical and biological evaluation of the preventive role of anti-cytomegalovirus specific immunoglobulins in bone marrow grafts. Randomized study of 60 patients].
    Bordigoni P, Janot C, Aymard JP, Witz F, Bené MC, Legras B, Schoonemann F, Olive D, Streiff F.
    Nouv Rev Fr Hematol (1978); 1987 Jul 15; 29(5):289-93. PubMed ID: 2830588
    [Abstract] [Full Text] [Related]

  • 15. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status?
    Novick RJ, Menkis AH, McKenzie FN, Reid KR, Ahmad D.
    J Heart Transplant; 1990 Jul 15; 9(6):699-706. PubMed ID: 2177496
    [Abstract] [Full Text] [Related]

  • 16. Passive immunization during pregnancy for congenital cytomegalovirus infection.
    Nigro G, Adler SP, La Torre R, Best AM, Congenital Cytomegalovirus Collaborating Group.
    N Engl J Med; 2005 Sep 29; 353(13):1350-62. PubMed ID: 16192480
    [Abstract] [Full Text] [Related]

  • 17. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients.
    López-Medrano F, Rueda B, Lizasoain M, Juan RS, Folgueira D, Andrés A, Morales JM, Jiménez C, Meneu JC, Aguado JM.
    Transpl Infect Dis; 2009 Oct 29; 11(5):400-4. PubMed ID: 19570139
    [Abstract] [Full Text] [Related]

  • 18. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Oct 29; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

  • 19. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients--a meta-analysis.
    Glowacki LS, Smaill FM.
    Clin Transplant; 1994 Feb 29; 8(1):10-8. PubMed ID: 8136560
    [Abstract] [Full Text] [Related]

  • 20. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.
    Transpl Infect Dis; 2000 Sep 29; 2(3):112-7. PubMed ID: 11429021
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.